Genetically detoxified pertussis vaccine that maintains intrinsic adjuvant activity
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9821056-B2
Publication Date
2017-11-21
Expiration Date
Abstract
The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.
Core Innovation
The invention describes a pertussis vaccine combining detoxified pertussis toxin with an S1 mutation, enzyme-treated pertussis lipopolysaccharide, and detoxified pertussis adenylate cyclase toxin. The described detoxification modifications are [procedural detail omitted for safety]. The vaccine is presented as retaining intrinsic adjuvant activity while reducing toxicity and reactogenicity.
The stated problem is to reduce toxicity and reactogenicity associated with the vaccine components while retaining their intrinsic adjuvant activity. The vaccine is described as intended for treatment or prevention of infection in a mammal, including pertussis infection. No further background discussion of the problem is provided in the supplied text.
Claims Coverage
The supplied relevant claims identify one independent claim, claim 1, comprising one inventive feature directed to a vaccine composition for treatment or prevention of infection in a mammal.
Vaccine combining detoxified pertussis components
The claim covers a vaccine comprising detoxified pertussis toxin with a mutation in subunit S1, enzyme-treated pertussis LPS, and detoxified pertussis adenylate cyclase protein (P-ACT). Specific modification details are omitted for safety.
The independent claim centers on the combination of three specified pertussis components in a vaccine for treatment or prevention of infection in a mammal.
Stated Advantages
The vaccine is described as retaining intrinsic adjuvant activity while reducing toxicity and reactogenicity.
Documented Applications
The vaccine is described for treatment or prevention of infection in a mammal, including pertussis infection.
Interested in licensing this patent?